StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $9.80 | $9.87 | +0.71% | 0.8M |
| 05-14 | $9.75 | $9.42 | -3.38% | 1.1M |
| 05-15 | $9.30 | $9.08 | -2.37% | 1.0M |
| 05-18 | $9.06 | $8.78 | -3.09% | 1.0M |
| 05-19 | $8.74 | $8.54 | -2.29% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 |
|---|---|---|---|---|
Revenue | $15.60M | $188.80M | $46.70M | $20.30M |
Operating Income | $-63.80M | $71.40M | $-188.40M | $-140.90M |
Net Income | $-57.60M | $82.90M | $-191.00M | $-138.00M |
EPS (Diluted) | $-0.90 | $1.14 | $-3.82 | $-2.81 |
Total Assets | $647.50M | $1.00B | $1.58B | $1.60B |
Total Liabilities | $260.70M | $341.00M | $799.90M | $787.13M |
Cash & Equivalents | $87.30M | $81.00M | $108.30M | $255.66M |
Free Cash Flow OCF − CapEx | $-70.50M | $-89.30M | $554.70M | $592.30M |
Shares Outstanding | 64.50M | 73.00M | 53.00M | 52.77M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.